Regenerative medicine: Disrupting the status quo in 2021By The Science Advisory Board staff writers
April 1, 2022
"The exciting advancements of 2021 demonstrate that regenerative medicine is here -- and it's not slowing down," said Janet Lambert, CEO of ARM.
The #cellandgenetherapy sector disrupted the status quo in 2021 with new milestones, including the first proof-of-concept for an in vivo gene editing therapy, evidence that #CARTcell therapies compare favorably with earlier line treatments, and compelling early results that cell and gene therapies could durably treat complex, polygenic diseases.
ARM's 2021 annual report provides a comprehensive look into the investment, scientific, and clinical landscape. The 2021 report is ARM's most in-depth review of the sector to date, with never-before-released data including a deep dive into the oncology space, a look at prevalent versus #raredisease targets, an update on the #geneediting field, information on #genetherapy delivery, and more.
Read the report on ARM's site.